Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
De Simone, C., Perino, F., Caldarola, G., D'Agostino, M., Peris, K., Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports, <<JOURNAL OF INTERNATIONAL MEDICAL RESEARCH>>, 2016; 44 (1_suppl): 67-71. [doi:10.1177/0300060515593250] [http://hdl.handle.net/10807/92635]
Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
De Simone, Clara
;Perino, FrancescaSecondo
;Caldarola, Giacomo;D'Agostino, MagdaPenultimo
;Peris, KettyUltimo
2016
Abstract
Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
